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 With chemotherapy and radiation being the most common forms of cancer treatment, 
some cancer cells are able to develop resistance and persist in the body. Because of this 
resistance, there is a need for a new cancer therapy that can attack these persistent cells. CAR T 
cell therapy utilizes the patient’s own immune system to attack and potentially eliminate these 
cancer cells. These cells have successfully been used against B cell malignancies, however, not 
much success has been seen when used against solid tumors. Solid tumors pose many challenges 
and threats these T cells must overcome in order to produce any anti-tumor effect. Challenges 
researchers run into include finding a suitable antigen to target, successfully trafficking to and 
infiltrating the tumor, and overcoming the microenvironment of the tumor. Researchers are 
continuously trying to figure out ways to overcome these challenges and increase the success of 




 In the United States, cancer is the second most common cause of death, estimating 
610,000 deaths in 2018 (Cancer Statistics, 2018). There is a necessity for a new and improved 
cancer treatment option. The primary forms of treatment for most types of nonsurgical cancers 
are chemotherapy and radiation. One of the disadvantages of these therapies is that cancers have 
been known to develop resistance over time. This development of resistance has created a strong 
need for a new, effective form of treatment that decreases relapse rate. However, there has been 
little advancement in the development of a form of treatment that is capable of completely 
eliminating lingering malignant 
cells. A promising form of treatment 
utilizes the patient’s own immune 
system, notably lymphocytes, to 
control and potentially eliminating 
malignant cells and the cancer all 
together (Figure 1) (Almåsbak, 
Aarvak, & Vemuri, 2016). Years 
ago, Gross and colleagues 
developed and demonstrated the idea of redirecting cytotoxic T lymphocytes to the tumor cells. 
They concluded their work with the statement, “Chimeric T cell receptors with antitumor 
specificity will enable testing feasibility of this approach in combating human tumors” (Gross, 
Waks, & Eshhar, 2006). Gross and colleagues laid the groundwork for a series of generations 
utilizing the immune system and cytotoxic T lymphocytes as a way to target tumor cells. First 
generation chimeric antigen receptors (CARs) were created by directly fusing a tumor targeting 
Figure 1. Production of CAR T cells in a GMP facility. Blood is taken from the 
patient (1) and is followed by T cell selection (2), and selection and activation 
of T cells (Davila, Bouhassira, et al., 2014). 
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antibody single chain variable fragment (scFv) to the signaling domain of the T cell receptor 
(TCR) signaling complex 
member CD3ζ (zeta). The first 
generation showed high target-
cell specific killing in vitro and 
showed preclinical efficacies in 
mouse tumor models, however, 
when these T cells were used 
clinically in ovarian cancer, the 
results were not nearly as 
promising (Kershaw et al., 2006). 
There was no reduction of tumor 
burden in 14 patients due to a lack of specificity trafficking of the T cells to the tumor and short 
persistence of the T cells. Further research determined that first generation T cells were 
susceptible to activation induced cell death (AICD) in the absence of exogenous costimulation 
(Park & Brentjens, 2015). After years of continuous research, second generation CAR expressing 
T cells were developed.  
 According to Essand and Loskog, second generation CARs were constructed to provide 
signaling through CD3ζ chain and CD28 costimulatory molecule by placing the signaling 
domains in series as a single gene multidomain product (Essand & Loskog, 2012) (Finney, 
Lawson, Bebbington, & Weir, 1998). This design was able to mediate 20 times more IL-2 
production upon stimulation with solid-phase antigen when compared with first generation 
CARs. It was discovered that second generation CARs with the costimulatory signals, from B7 
Figure 2. The various CAR T generations developed. First generation CARs have a 
single chain variable fragment. Second generation CARs differ from first generation 
CARs by the presence of a single costimulatory domain. Third generation CARs take 
second generation CARs one step further by having two costimulatory domains 
(Maus, Grupp, Porter, & June, 2014). 
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and tumor necrosis factor receptor (TNFR), in series with CD3ζ, promote self-sufficient clonal 
expansion and enhanced effector function in resting human T cells. In order to create the most 
effective second generation CAR T cells, studies were done to compare various signaling 
domains. Various studies reported increased persistence, tumor localization, and antitumor 
activity of CAR T cells with a 4-IBB signaling domain when compared with CARs with CD28 
signaling domain (Essand & Loskog, 2012).  
 As a way to try and improve second generation CARs, third generation CARs were 
constructed containing a CD3ζ chain, CD27, CD28, ICOS, and OX-40 or 4-IBB signaling 
domain (Figure 2). Ideally, these receptors would provide a full complement of activation, 
proliferation, and survival signals for enhanced antitumor activity; however, using third 
generation CARs has been somewhat disadvantageous. Despite the promising preclinical results, 
there were concerns of triggering lethal cytokine storms within patients treated. Another concern 
of the third generation CARs, is the reduction of the signal threshold to a level at which the 
activation of grafted T cells can occur without triggering antigens (Essand & Loskog, 2012).  
 With these advances in CAR T cell technology and the many studies that have been 
performed using all three generations of CAR, these cells have been successful or on the road to 
success when treating blood borne and solid tumors. For B-cell malignancies, CAR T cells are 
expected to be a mainstream therapy, especially for refractory or relapsed B-cell malignancies 
(Almåsbak et al., 2016). By changing the antigen T cells target, CARs can be used for many 
different types of cancers, both hematologic and solid. Though treatment of hematologic cancers 
with CAR T cells has been more successful, treating solid cancers has posed difficult challenges 





 CAR T cells have changed the 
way various cancers are treated. The 
targeting of tumor cells begins when a 
CAR on a T cell binds to its antigen on 
the tumor, leading to signaling and 
activation. Activation can lead to the 
killing of tumor cells through the release 
of granzyme and perforin or by the 
activation of other immune system 
components by CD4+ T cell cytokine 
release. The use of T cells can lead to the formation of memory T cells, developing long-lived T 
cells that are specific to that specific tumor type (Figure 3) (Davila, Bouhassira, et al., 2014). 
 
Treatment of B cell malignancies with CAR T cells 
Using the mechanism described above, CAR T cells have shown much promise and are 
expected to be the mainstream treatment. B cell malignancies include B cell acute lymphoblastic 
leukemia, B cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and Hodgkin’s 
lymphoma. Many of the studies conducted (65%) that involved T cell therapy were directed 
towards hematological malignancies. Of those studies, CD19 was the most common antigen 
targeted in B cell cancers, used over 80% of the time. There are studies to investigate other 
potential target antigens, such as CD20, CD22, CD30, ROR1, κ light chain, CD123, CD33, 
Figure 3. The recognition of tumor cells can lead to two possible outcomes: 
activation of cytotoxic T cells or cytokine release recruiting other immune 
cells (Davila, Bouhassira, et al., 2014). 
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CD133, CD138, and B-cell maturation antigen (Berger et al., 2014) (Dotti, Gottschalk, Savoldo, 
& Brenner, 2014) (Carpenter et al., 2013). The most successful outcomes have come by targeting 
CD19, CD20, or CD30, however, the most advancement has been seen by using CD19-specific 
CAR T cells for B cell acute lymphoblastic leukemia with complete remission rates of 70-94% 
(Z. Wang, Wu, Liu, & Han, 2017). One of the first successful studies of the use of CD19 was 
conducted at the National Cancer Institute in 2010. Follicular lymphoma patients were treated 
with this form of CAR T cell therapy, developing partial remission after receiving chemotherapy 
and an infusion of retrovirally transduced T cells that expressed a second generation CD19 CAR 
with a CD28 costimulation domain (Kochenderfer et al., 2010). Shortly after this study showed 
success, a group at the University of Pennsylvania showed antileukemia efficacy in T cells 
transduced with a lentiviral vector carrying a CD19 CAR with a 4-IBB costimulation domain 
(Kalos, Levine, et al., 2011) (Kalos, June, Levine, Bagg, & Porter, 2011). Of the three end-stage 
advanced chronic lymphocytic leukemia patients treated, two developed complete remission and 
the other developed a partial response. This study exhibited the expansion of CAR T cells in vivo 
correlated with clinical responses (Almåsbak et al., 2016).  
 
Treatment of solid tumors with CAR T cells 
 Much success has been shown with blood-borne tumors, but little has been seen with 
solid tumors. There has been a steady rise in the number of clinical trails that focus on solid 
tumors. These clinical trials target carcinoembryonic antigen, diganglioside GD2, mesothelin, 
interleukin 13 receptor α (IL13Rα), human epidermal growth factor receptor 2 (HER2), 
fibroblast activation protein, and L1 cell adhesion molecule (Gill, Maus, & Porter, 2016) (Fousek 
& Ahmed, 2015). Despite these trials, little success has been achieved. The two more successful 
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trials have used GD2 CARs to target neuroblastoma, 3 of 11 patients develop complete 
remission, and HER2 CARs for sarcoma, 4 of 17 patients showing stable disease (Louis et al., 
2011) (Ahmed et al., 2015). The reasons for such little success are yet to be discovered and pose 
to have many factors. When compared to blood-borne malignancies, solid tumor landscapes 
contain many barriers (Newick, Moon, & Albelda, 2016). In order for CAR T cells to impact 
solid tumors, they must successfully travel to the site of the tumor regardless of potential T-cell 
chemokine receptor-tumor-deprived chemokine mismatches. Also, CAR T cells must infiltrate 
the stromal elements of the tumors in order to elicit tumor-associated antigens-specific 
cytotoxicity, despite antigen loss of heterogeneity. Even if the CAR T cells make it to the tumor 
and are able to infiltrate it, the T cells must overcome the environment, the presence of 
suppressive soluble factors and cytokines, suppressive immune cells, and T-cell intrinsic 
negative regulatory mechanisms and overexpression of inhibitory molecules. Within the 
environment of the tumor, there is oxidative stress, the T cells would have to overcome 
nutritional depletion, and the T cells would experience a low pH and hypoxia (Newick et al., 
2016) (Knochelmann et al., 2018). 
 
Difficulties faced when treating solid tumors with CAR T cells  
 One of the obstacles that must be overcome when using CAR T cell therapy against solid 
tumors is determining which tumor-associated antigen is optimal and would be the most 
effective. In blood-borne malignancies, CD19 is consistently expressed, leading to effective 
treatment with CD19 CAR T cells. However, with solid tumors, identifying specific antigens to 
target has posed a challenge. Currently, 30 different tumor-associated antigens have been 
identified. Of the 30 recognized and evaluated, neoantigens were particularly attractive to use for 
Bonnett 8 
CAR T cell therapy because they are only expressed on tumor cells (Restifo, Dudley, & 
Rosenberg, 2012). With further research, neoantigens were discovered to be a product of tumor-
specific mutations and are highly individualized, not making them an ideal target of CAR T cell 
therapy. Despite tumor-specific mutations of neoantigens, many generalized neoepitopes have 
been identified (Newick et al., 2016). 
 Instead of using only tumor-specific antigens, antigens expressed only during 
developmental growth have been potential targets of CAR T cell therapy. An example of an 
antigen expressed during development and is restricted in normal adult tissues is CEA. This has 
been a target for mouse studies, showing evidence of tumor eradication by CEA-CAR T cells 
(Chmielewski et al., 2012). Targeting this antigen has caused serious side effects, specifically 
transient colitis, in three metastatic colon cancer patients (Parkhurst et al., 2011). Other types of 
antigens have been researched and are currently being tested in mouse studies and clinical trials 
(Newick et al., 2016). 
 As soon as an antigen has been identified, generated, and infused into a cancer patient, a 
major obstacle that is immediately encountered is the ability of the CAR T cells to get to the 
tumor and successfully infiltrate it. This process is dependent on the expression of adhesion 
receptors on T cells and the tumor endothelium, and a “pairing” between the chemokine 
receptors on the CAR and the chemokines tumors secrete. However, there is often a mismatch of 
chemokine/chemokine receptor, with tumors producing very small amounts of ligands that 
enhance CD8+ recruitment (Harlin et al., 2009). Often times, tumors that express less 
chemokines evade host surveillance by impairing the recruitment of effector T cells and their 
ability to infiltrate the solid tumor. Some chemotherapy drugs are able to enhance the 
recruitment of CD8+ T cells and reduce tumor growth by inducing CXCR3-ligand and CCL5 
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(Hong et al., 2011). Studies have shown that two groups enhance the infiltration of T cells and 
augment antitumor activity of the CAR T cells, these groups are GD2 in neuroblastoma and 
CCR2 on CAR T cells (Craddock et al., 2010). One of the main struggles scientists face is the 
individuality of each form of cancer (Knochelmann et al., 2018). In order to create effective 
CAR T cells and traffic them to the correct areas, where the solid tumors are located, the unique 
chemokine profiles have to be determined and understood.  
 Once the CAR T cells have made it to the solid tumors, another obstacle is run into, the 
microenvironment of the tumor. Normally, the microenvironment of the tumor is hostile, both 
physically and metabolically. A couple of physical barriers the T cells must overcome are stroma 
and high tissue pressure that prevents extravasation. To overcome these barriers, some studies 
used FAP-CAR T cells to reduce the number of tumor fibroblasts. Other studies used specific 
CAR T cells that secrete an enzyme that degrades the matrix. These two methods, FAP-CAR T 
cells and enzyme secreted CAR T cells, have only been tested in animal models, they have yet to 
be tested on humans (L.-C. S. Wang et al., 2014) (Caruana et al., 2015).  
 Despite the hostility of the physical environment of the tumor, the metabolic landscape 
poses a threat to the viability of CAR T cells. Tumor microenvironments are, often times, rich in 
suppressor cytokines, such as TGF-β and IL-4, and inhibitory molecules, such as PD-L1. PD-L1 
helps the tumor escape the host immune system. In order to overcome this, researchers have 
added domains to the CAR T cells. These domains either limit suppressive signaling or convert 
the suppressive signals into activating signals (Foster et al., 2008). Recently, studies have used a 
chimeric cytokine receptor to bind IL-4. When IL-4 binds the receptor, the therapeutic IL-7 
signal pathway phosphorylates STAT5 and polarizes the cell toward an inflammatory Th1 
response (Leen et al., 2014). Another similar study was done using a PD-1/CD28 chimeric 
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switch receptor. This switch receptor was designed to convert an exhaustive stimulus into a 
costimulatory signal, enhancing cytokine production and efficacy (Liu et al., 2016) 
(Knochelmann et al., 2018). 
 Though the suppressive cytokines are a major hurdle that must be overcome in order for 
the CAR T cells to survive the tumor microenvironment, other microenvironment issues include 
hypoxia and nutrient starvation. Because of hypoxia and nutrient starvation, the generation of 
lactate is increased, leading to acidosis within the tumor (Fischer et al., 2007). The deficiency in 
nutrients, specifically tryptophan, arginine, and lysine, can activate the integrated stress response 
within the T cells. The activation of the integrated stress response can cause shutdown of 
translation and stimulate an autophagy response in effector T cells as a way to generate a source 
of nutrients (Howie, Waldmann, & Cobbold, 2014) (Newick et al., 2016).  
 
Adverse effects of CAR T cells 
 CAR T cells have provided a way to attack refractory or relapsed malignancies, but there 
are some adverse effects of using CARs. These adverse effects can be immediate or delayed, 
mild or severe, or persist for a short or long period of time. One of most prevalent adverse effects 
is the onset of immune activation, known as cytokine release syndrome (Lee et al., 2014). This 
results in the increase in inflammatory cytokines, specifically IL-10 and IL-6. Clinical features 
include high fever, malaise, fatigue, myalgia, nausea, anorexia, tachycardia, capillary leak, and 
many more. The severity of CRS is determined by the burden of the disease at the time of 
infusion; patients with high tumor burden experience more severe CRS. Researchers have been 
studying the use of IL-6R blockade as a treatment for CRS while looking at its effect on 
proliferation, persistence, and antitumor effect (Maude, Barrett, Teachey, & Grupp, 2014).  
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 Another adverse effect reported with the use of CAR T cell therapy is on-target/off-tumor 
recognition. This often occurs because the epitope targeted by the CAR T cells is often shared 
with normal cells in other tissues (Curran, Pegram, & Brentjens, 2012). The severity of this on-
target/off-tumor ranges from manageable lineage depletion to severe toxicity possibly leading to 
death. This is often seen in various organ systems: gastrointestinal, pulmonary, and hematologic. 
On-target/off-tumor recognition was seen in one trial utilizing a carboxyanhydrase-IX-specific 
CAR T cell for renal cell carcinoma. This utilization of these specific CARs led to the 
development of cholestasis because of carboxyanhydrase-IX expression on bile duct epithelium 
(Lamers et al., 2006). An example of manageable lineage depletion was seen when CD19-
specific CAR T cells were used. The CD19-specific CARs targeted normal B cells resulting in 
B-cell aplasia, which required an infusion of pooled immunoglobulin as prophylaxis from 
infectious complications (Kochenderfer et al., 2010). On the other hand, on-target/off-tumor 
recognition can be lethal. An example of this was seen in a patient treated with CAR T cells 
specific for the cancer-associated antigen HER-2/neu. This patient quickly developed respiratory 
failure and multi-organ dysfunction, ultimately leading to death. The death of the patient was 
attributed to reactivity against pulmonary tissue expression of HER-2/neu and the high dose of 
infused CAR T cells (Morgan et al., 2010).  
 Recent technological advances in T cell engineering with retroviral and plasmid vectors 
allow the generation of high numbers of tumor targeting T cells by introducing tumor specific T 
cell receptors (TCR) or CARs. CARs exhibit high-affinity major histocompatibility complex 
(MHC) independent recognition of any surface antigen (Almåsbak et al., 2016). The use of 
retroviral vectors has produced adverse effects within patients, from the retroviral vector 
insertion near the LMO-2 oncogene. The risk of transgene insertion into differentiated T cells 
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leading to induced malignant transformation has been a concern of researchers. However, there 
have been no reported cases of transformation after the infusion of genetically modified T cells. 
This can be due to the fact that the LMO-2 oncogene is silent in T cells, therefore, making it an 
undesirable location of retroviral integration. Overall, the risk of insertional oncogenesis 
following gene transfer into T cells is low, but there is still a risk it may occur (Scholler et al., 
2012). 
 
Managing toxicity of CAR T cell therapy 
 Of the adverse effects cited above, there are a few more worth mentioning. Following 
CAR T cell therapy, there is a risk of neurological toxicity, anaphylaxis, and off-target antigen 
recognition (Bonifant, Jackson, Brentjens, & Curran, 2016). Though there are many risks to be 
concerned about, there are many measures being taken to manage toxicity and these adverse 
effects, especially in hematologic malignancies. The most common toxicity developed by 
patients after the administration of CD19-specific T-cells is the uncontrolled immune activation 
in the form of cytokine release syndrome. Tocilizumab had demonstrated IL-6R blockade, 
resulting in the reversal of cytokine release syndrome symptoms. Corticosteroids have also been 
used and have demonstrated immunosuppressive qualities. However, the prolonged use of 
corticosteroids has resulted in the diminished persistence and efficacy of CAR T cells (Davila, 
Riviere, et al., 2014).  
 As this technology has progressed and developed through the years, the integration of 
suicide genes has allowed for the selective depletion of CAR T cells, helping with the wide range  
of toxicities that can develop (Marin et al., 2012). Another way to selectively deplete CAR T 
cells is to program these cells to express a CD20 and EGFR cell-surface antigens with the 
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triggering of cell death via the infusion of the associated monoclonal antibody. The expression of 
these cell-surface antigens allows for the selection and tracking of the genetically modified T 
cells (Philip et al., 2014).  
 
CAR T cell therapy in dogs 
 The development and use of CAR T cells in humans has sparked interest in using this 
therapy in canines. Canine cancers closely parallel those in humans through the biology, 
behavior, and genetic aspects. In dogs, Non-Hodgkin’s Lymphoma is the most common cancer 
and has posed many difficulties when treating. Combinations of chemotherapeutic agents have 
shown success by leading to remission in about 75% of dogs, however, most dogs relapse within 
six to nine months. Dr. Nicola Mason, a professor at eh University of Pennsylvania’s School of 
Veterinary Medicine, and Dr. Avery Posey, an instructor at the University of Pennsylvania’s 
School of Medicine, have developed CAR T cell therapy for canine use. In 2018, a first-in-dog 
clinical trial took place at the University of Pennsylvania School of Veterinary medicine. Patients 
had relapsed, refractory B cell lymphoma or leukemia. Much success was seen in the preliminary 
results, but further research must be done to improve the persistence and function of these CAR 
T cells. With the use of these canine models, veterinary oncologists and researchers hope to 
establish better therapeutic platforms that will improve the effectiveness in both blood-borne 
cancers and solid tumors and reduce side effects in both humans and canine patients (Lee & 






 CAR T cell therapy is a cancer treatment option that will someday become mainstream 
for many types of cancers. In order for this to be achieved, the safety and efficacy of this 
treatment has to be improved, and with further research, it will be. Thus far, CAR T cells have 
demonstrated efficacy and success in various hematological cancers. Clinical data seems 
promising in solid tumors, including neuroblastoma and tumors overexpressing mesothelin, 
HER2 and EGFR. However, utilizing CAR T cells for solid tumors has posed quite a challenge 
and has not shown much success. As research continues, more types of cancers will be targeted 
and the safety and efficacy will be increased. In order for this treatment to be effective, it must 
work at the cellular level and it has to be affordable. As this treatment becomes more mainstream 
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